Drug Discovery AI
E

Evozyne

Evozyne is a Chicago biotechnology company, founded by Paragon Biosciences in 2020, that designs new therapeutic proteins with generative AI and its own laboratory. EvoGen, its design engine, generates candidate proteins and estimates their potency, specificity, stability and immunogenicity, and EvoLab runs high throughput experiments whose results feed the next design round. Evo TestBench compares modeling approaches against experimental results across several kinds of design problem before a project commits to one. Partners gain access to the platform, its immunology expertise and its experimental capacity through research collaborations, which the company continues to seek in immunology, protein engineering and newer biologics.

Takeda's research and license collaboration on rare disease targets produced two highly functional proteins within six months. With NVIDIA, Evozyne built ProT-VAE, a transformer variational autoencoder on the BioNeMo framework, and its October 2025 PNAS paper reports a phenylalanine hydroxylase design with 2.5 times the catalytic activity of the natural enzyme and a carbonic anhydrase 61 °C more heat stable than the most stable known sequence. Gates Foundation supported work on heat tolerant proteins appeared in microPublication Biology.

Its own pipeline targets immune mediated diseases where biologics fail, including IgG mediated disorders, inflammatory bowel disease and engineered cytokines, with a first investigational new drug filing planned for 2026. Marc Yoskowitz is chief executive, and an $81 million Series B in 2024 was led by OrbiMed and Fidelity with NVIDIA's NVentures taking part.

AI Health Index verifiedNovember 20, 2026
Compare Evozyne with other vendors
Founded
2020
Headquarters
Chicago, Illinois, US
Website
evozyne.com/
Categories
drug-discovery
Indexed Products
EvoGen, EvoLab
Buyer Segments
Pharmaceutical Company, Biotechnology Company, Research Organization
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
AA on AI CentralityThe artificial intelligence is the product. Remove the model and there is nothing left to sell.
Vendor Published

Generative protein design is what a partner buys into. EvoGen generates candidate proteins for a therapeutic objective and estimates their potency, specificity, stability and immunogenicity so the team can choose which designs to make, and EvoLab's high throughput experiments test those designs and feed the results into the next round.

A collaboration delivers tested research candidates rather than a model subscription, with experimental capacity and scientific expertise included, but turning a research objective into a set of proposed proteins in the first place is the model's work.

BB on Autonomy and Oversight ModelThe oversight structure is described and one part is missing, commonly the threshold at which the system stops or what happens after it is wrong.
Vendor Published

Model proposals pass through laboratory evaluation before a project judges whether a candidate has the intended properties: EvoLab runs the tests, and research teams use the measurements to pick which designs to pursue. Evo TestBench compares model performance against experiment so researchers choose an approach suited to the project, and scientific decisions and the move into development stay with the research team. No standard partner approval threshold or quantitative stop rule decides which proposals enter a new laboratory stage; each project sets its own gates.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

EvoGen is the generative design engine, and the ProT-VAE work with NVIDIA, published in PNAS, names its transformer and variational autoencoder architecture built on the BioNeMo framework. Experimental results feed back to refine the models, and Evo TestBench compares several approaches instead of treating one as right for every project, so the technology behind a collaboration varies with the task. There is no full list of production models, release history or account of the datasets behind a partnership, so a partner cannot tie a change in output to a model update.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

Evozyne runs EvoGen inside its own research and laboratory operation, an in house chain from model to experiment. NVIDIA helped develop the ProT-VAE architecture and its BioNeMo framework underpins the models, as the published research sets out, which identifies a development partner rather than a party receiving current partner inputs. No full list of compute hosts, model components and data processors reaches a partner, and no standard term names outside recipients or their retention and training rights for each step.

BB on Clinical and Operational EvidenceNamed deployments with dated outcome figures and enough method to test them, or published research short of independent validation.
Peer Reviewed Publication

The Takeda research and license collaboration is named, and Evozyne reports it produced two highly functional proteins within six months. With NVIDIA, the company published ProT-VAE, the architecture behind EvoGen, in PNAS in October 2025: a designed phenylalanine hydroxylase reached 2.5 times the catalytic activity of the natural enzyme, and a carbonic anhydrase gained 61 °C in melting temperature over the most stable known sequence.

Gates Foundation supported work appeared in microPublication Biology. These are laboratory results for parts of the platform, with no evidence yet for the current workflow's clinical candidates or for benefit in patients.

DD on AI Safety and PHI StewardshipNothing published on how protected information moves through the system.
Vendor Published

EvoLab returns experimental observations on research candidates to the discovery program, and those measurements inform the next EvoGen rounds. The privacy policy treats that experimental data separately from information visitors submit through the website, and its retention language reaches only the website.

No standard collaboration term sets de identification for contributed patient information, a retention period for partner research inputs or limits on reusing partner datasets, and the platform's safety testing concerns candidate properties, with no stated process for a partner data incident.

Regulatory and Compliance
DD on HIPAA and BAA PostureNo statement of status and no privacy document that reaches the product. Both halves are absent at this grade: a service level privacy document on its own lifts a vendor to the band above even where no status is stated. A website privacy notice, including one that says it does not cover customer data, does not reach the product, so a vendor whose only document is that notice and who states no status grades here.
Vendor Published

Pharmaceutical and biotechnology partners reach the design platform through research collaborations that test candidate proteins and compare their experimental properties, with no clinical record workflow or patient portal. The general privacy policy covers visitors, contacts and site users and sets no terms for protected health information in a partner project. No business associate relationship or BAA tier is stated, and no collaboration commitment says which identifiable patient information, if any, a partner may introduce.

DD on Security Certifications and Trust CenterControls are asserted with nothing independent behind them, or nothing is published. Read the note before concluding anything: this is the grade most often corrected on a second pass, because assurance material frequently sits on a parent domain or inside an old announcement rather than on the product pages.
Vendor Published

A collaboration can carry commercially sensitive target information, research inputs and experimental results through a scientific workflow Evozyne runs on its own proprietary datasets. The website privacy policy covers contact and browsing data, and research terms depend on each partner agreement.

No SOC 2 report, ISO 27001 certificate or security audit covers EvoGen and EvoLab, and there is no stated cadence of independent security testing or description of the controls on collaboration data moving between modeling and the lab.

CC on FDA and Regulatory StatusNo device claim is made and the product is scoped accordingly. Most administrative and operational products sit here and are not penalized for it, because this axis grades the appropriateness of the positioning rather than possession of a clearance. A stated limit on use, such as research use only or a clause that the product gives no medical advice, beside marketing that sells the product for clinical decisions also sits here, with both quoted, because the buyer has to ask which one governs.
Vendor Published

EvoGen and EvoLab support discovery and preclinical testing, and partner work concerns research candidates for later development. Evozyne plans its first investigational new drug submission in 2026 for an internal immunology program, a filing that would cover a drug candidate rather than the research platform. Selecting a candidate says nothing yet about its safety or effectiveness in patients, and the platform carries no diagnostic or treatment device indication.

BB on AI Governance and Bias DisclosureA governance framework with named process behind it, such as certification to an artificial intelligence management standard, or material written for a customer own review committee to evaluate the product with. A framework covering the vendor whole portfolio counts when its scope reaches this product; what it cannot supply is the product specific evaluation the band above asks for. Published results within the one group where the performance of this product is most at risk also sit here: evaluation on the question this axis asks, short of the comparison across groups the band above requires. A medical device clearance or certification, and the quality system behind it, does not reach this band on its own; it is graded under regulatory status. A regulator reviewed plan governing how the model may change does reach it.
Vendor Published

Evo TestBench is a defined process for comparing modeling approaches against experimental results across several categories of therapeutic design problem, and it decides which models a project relies on, since approaches perform differently from task to task. EvoGen also carries immunogenicity prediction modules, with stability and sequence risks tested early and often. The program is internal, with no external audit, and its testing covers laboratory design tasks rather than how a candidate behaves across the patient populations a future treatment would reach.

CC on AI Liability and RecourseMechanisms exist that let someone challenge an output, such as audit trails, source traceability or review before commit, with nothing standing behind the output and no route for the harmed party.
Vendor Published

Experimental testing lets the research team reject an AI proposal that misses the project's scientific objective and send a candidate through another round. In a partnered program such as Takeda's, rights and obligations sit in a negotiated research and license agreement, while the website disclaimer reaches only site content and use. No accuracy guarantee or stated remedy covers a partner whose candidate fails a design or laboratory objective, and the terms of any commissioned program stay inside its own contract.

Integration and Deployment
DD on EHR and Interoperability DepthNo integration evidence. A connector described as available on request grades here until one exists.
Vendor Published

The customer workflow is a research collaboration, with software and laboratory work running inside Evozyne's own discovery process and results evaluated with the partner. Nothing in it works from a patient chart: there are no EHR connections, HL7 or FHIR interfaces or exchange with a health system's clinical software, and laboratory data moves back into modeling internally. Partners receive research results, not a tool installed in clinical systems.

DD on Deployment Model and Data ResidencyNothing published about where the system runs or where the data rests.
Vendor Published

Collaborations run on a discovery environment and laboratory Evozyne operates in Chicago, with partners working through the project team and results feeding later EvoGen rounds. EvoGen's model was built on NVIDIA's BioNeMo framework, which says nothing about where partner data is stored or processed. There is no customer hosted or local version, no committed storage or inference region and no stated method for isolating one partner's computation and research material from another's.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

Partners commission research through a collaboration that can draw on EvoGen, EvoLab and Evozyne's scientists, with access and intellectual property governed by a negotiated license, and the Takeda agreement was built around a defined group of rare disease targets. The company seeks collaborations in immunology, protein engineering and newer biologics, and a buyer reaches the team directly rather than opening a software account. No standard platform license fee, per project price or milestone schedule is stated for a new collaboration.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

The setting is biopharma research and preclinical development. Internal programs focus on immune mediated diseases where biologics fail or lose effect, including IgG mediated disorders, inflammatory bowel disease and engineered cytokines, while the Takeda collaboration applied the approach to rare disease targets and the NVIDIA work to enzyme design in the lab. Partners without a comparable platform get scientific and laboratory support with the research. Results so far cover parts of discovery, with no clinical validation across the diseases on the pipeline.

Alternatives

Alternatives to Evozyne

Other products that do the same kind of work as Evozyne, and what each one does.

Scala Biodesign makes software that redesigns proteins to work better, and sells it both as a cloud platform and as a design service.

BioGeometry builds generative AI models for protein design and uses them in partner projects and its own drug pipeline.

Earendil Labs uses AI to design antibody drugs and develops them through its own pipeline, licensing individual programs to large pharmaceutical companies.

Terray Therapeutics is a Los Angeles small molecule company whose founding argument is about data rather than models. Its chief executive Jacob Berlin put it plainly at the Series A: even the most powerful artificial intelligence cannot get past insufficient or unclear data.

Variational AI develops Enki, a generative model for designing small molecules against a research team's target product profile.

immunitoAI designs antibody drugs with AI and tests the designs in its own laboratory.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Negotiated research collaboration
Partners negotiate the scope of a discovery program and any license rights. The Takeda agreement was organized around a defined group of rare disease targets. A standard rate is unavailable. The offering is a research collaboration with no stated BAA tier. EvoGen modeling and EvoLab experimental work are part of the negotiated program. Separate onboarding or laboratory fees depend on the agreement. Vendor Published

Evozyne supplies research and laboratory capacity through collaborations. Buyers engage directly to define scope, deliverables and licensing. There is no standard software seat price.